Clinical trial ETOP 22-22 ADEPPT
A multicenter, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (> 70 years) or patients with poor performance status mutations. (IBCSG - ETOP 22-22 ADEPPT)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | ETOP-IBCSG Partners Foundation |
| EudraCT Identifier | 2022-002736-31 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05673187 |
| Last update |